Quantcast
Last updated on April 16, 2014 at 14:14 EDT

Latest Nephrotic syndrome Stories

2013-08-27 08:26:39

ANAHEIM, Calif., Aug. 27, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Morgan Stanley Global Healthcare Conference in New York City on September 10, 2013 at 4:40 PM ET/1:40 PM PT. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. About Questcor...

2013-05-29 08:30:06

ANAHEIM, Calif., May 29, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that its Board of Directors has declared a quarterly cash dividend of $0.25 per share to shareholders of record at the close of business on July 22, 2013. The dividend is scheduled to be paid on or about July 30, 2013. About Questcor Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat...

2013-05-08 16:27:50

ANAHEIM, Calif., May 8, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas on May 14, 2013 at 4:20 PM PT/7:20 PM ET. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event. About Questcor...

2013-01-28 08:28:13

ANAHEIM, Calif., Jan. 28, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the appointment of Michael Aldridge to the new position of Senior Vice President, Corporate Strategic Development. Mr. Aldridge's primary responsibilities will be the identification and development of partnership and acquisition opportunities to leverage Questcor's business model. Over time, such initiatives may include development programs or products complementary to Acthar (H.P....

2013-01-03 08:24:59

ANAHEIM, Calif., Jan. 3, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 10, 2013 at 9:00 a.m. PT / 12:00 p.m. ET. A live webcast with accompanying slide presentation, and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available...

2012-12-21 11:18:13

Additional studies are needed to find better treatments Highlights: -Six months of steroid treatment in children with nephrotic syndrome did not reduce relapse rates or side effects compared with three months of treatment. -Because many children with nephrotic syndrome face frequent relapses, future research should focus on preventing relapses through new treatment strategies. -Nephrotic syndrome has an estimated incidence of two to seven cases per 100,000 children and a prevalence of...

2012-11-30 16:22:22

Engaged Donor Continues Support of Kidney Disease Non-Profit NEW YORK, Nov. 30, 2012 /PRNewswire-USNewswire/ -- The NephCure Foundation took center stage on the New York City philanthropy scene Wednesday night, hosting prominent philanthropist Stewart Rahr and several New York City sports and entertainment stars at its eighth annual Countdown To A Cure benefit gala at Capitale in Manhattan. Raising funds for research into the kidney disease FSGS and Nephrotic Syndrome, the NephCure...

2012-10-15 07:28:23

ANAHEIM, Calif., Oct. 15, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release third quarter 2012 financial results on Tuesday, October 23, 2012 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, October 23, 2012 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments. The...

2012-09-28 02:24:54

ANAHEIM, Calif., Sept. 28, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that its Board of Directors has adopted a policy to pay a regular quarterly dividend in such amounts as the Board of Directors may determine from time to time. The Board of Directors has declared an initial quarterly cash dividend of $0.20 per share to all shareholders of record at the close of business on October 31, 2012. The initial dividend will be paid on or about November 15,...

2012-09-19 14:21:40

ANAHEIM, Calif., Sept. 19, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will conduct a conference call to discuss the reimbursement process for H.P. Acthar Gel (repository corticotrophin injection) prescriptions. The call will take place on Thursday, September 20, 2012 at 11 a.m. ET, 8 a.m. PT. The call can be accessed in the following ways: By webcast: At Questcor's investor relations website: http://ir.questcor.com/. By telephone: For both...